Insider Selling: TransMedics Group, Inc. (NASDAQ:TMDX) Insider Sells $6,866,240.40 in Stock

TransMedics Group, Inc. (NASDAQ:TMDX) insider Tamer I. Khayal sold 63,260 shares of the firm’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $108.54, for a total transaction of $6,866,240.40. Following the sale, the insider now owns 9,792 shares of the company’s stock, valued at $1,062,823.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

TransMedics Group Price Performance

Shares of NASDAQ TMDX opened at $127.99 on Monday. The stock’s 50-day simple moving average is $85.54 and its 200-day simple moving average is $77.32. The firm has a market capitalization of $4.19 billion, a PE ratio of -376.44 and a beta of 1.87. TransMedics Group, Inc. has a fifty-two week low of $36.42 and a fifty-two week high of $129.66. The company has a debt-to-equity ratio of 3.69, a quick ratio of 8.49 and a current ratio of 9.30.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings data on Tuesday, April 30th. The company reported $0.35 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.40. The company had revenue of $96.90 million during the quarter, compared to the consensus estimate of $83.78 million. TransMedics Group had a negative net margin of 3.43% and a positive return on equity of 8.29%. TransMedics Group’s revenue for the quarter was up 132.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.08) earnings per share. As a group, equities research analysts forecast that TransMedics Group, Inc. will post 0.62 EPS for the current fiscal year.

Hedge Funds Weigh In On TransMedics Group

A number of institutional investors have recently modified their holdings of TMDX. J.W. Cole Advisors Inc. acquired a new position in TransMedics Group in the 3rd quarter valued at about $929,000. Bank of New York Mellon Corp lifted its holdings in shares of TransMedics Group by 91.4% during the third quarter. Bank of New York Mellon Corp now owns 760,099 shares of the company’s stock worth $41,615,000 after purchasing an additional 363,012 shares during the period. Shariaportfolio Inc. purchased a new position in TransMedics Group in the 3rd quarter valued at $470,000. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in TransMedics Group by 12.4% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,913 shares of the company’s stock valued at $378,000 after buying an additional 763 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in TransMedics Group by 12.8% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 14,940 shares of the company’s stock worth $818,000 after buying an additional 1,700 shares during the last quarter. 99.67% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

TMDX has been the topic of several research analyst reports. Canaccord Genuity Group boosted their price objective on TransMedics Group from $102.00 to $117.00 and gave the company a “buy” rating in a report on Wednesday, May 1st. JPMorgan Chase & Co. lifted their target price on TransMedics Group from $105.00 to $127.00 and gave the company an “overweight” rating in a report on Wednesday, May 1st. TD Cowen upped their price target on TransMedics Group from $100.00 to $130.00 and gave the stock a “buy” rating in a report on Wednesday, May 1st. Oppenheimer lifted their price objective on TransMedics Group from $105.00 to $125.00 and gave the company an “outperform” rating in a research note on Wednesday, May 1st. Finally, Morgan Stanley upped their target price on shares of TransMedics Group from $75.00 to $95.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 28th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, TransMedics Group has an average rating of “Moderate Buy” and an average price target of $119.00.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.